Phase II Study of Ibritumomab Tiuxetan (Zevalin) in Patients With Previously Untreated Marginal Zone Lymphoma.

Trial Profile

Phase II Study of Ibritumomab Tiuxetan (Zevalin) in Patients With Previously Untreated Marginal Zone Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
  • Indications Marginal-zone-B-cell-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Dec 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 18 Apr 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 04 Aug 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top